Purpose: The purpose of this study is to assess changes in tear film stability caused by incomplete blinking.
Methods: Eleven subjects (mean age, 21.3 years) participated in this study. All subjects had a visual acuity of 20/20 or better and normal ocular health. The subjects were asked to play a game for 60 min on a personal computer as part of a visual display terminal (VDT) experiment. Each subject's blinking was observed by a Web camera that was attached to the top of the display. Every 15 min, the VDT experiment was interrupted for measurement. An RT-7000 (Tomey Co., Ltd., Nagoya, Japan) was used to measure ring breakup time as a parameter of tear film stability. An OPD-Scan II ARK-10000 (NIDEK Co., Ltd., Aichi, Japan) was used to measure corneal aberrations.
Results: Although the total blink rate changed very little, the complete and incomplete blink rates fluctuated during the VDT experiment. Both types were plotted along symmetrical cubic approximation curves. Noninvasive (ring) breakup time at 30 min (4.33 ± 2.57 s) was significantly shorter (p < 0.01) than that at baseline before the VDT experiment (8.62 ± 1.54 s). After 30 min, the incomplete blink rate began decreasing (fewer incomplete blinks), whereas the complete blink rate began increasing. Ring breakup time increased (improved) after 45 min; however, the incomplete blink rate began to increase again after approximately 50 min.
Conclusions: Even if the total blink rate decreases, the tear film remains stable so long as almost all blinks are complete. The incomplete blinking contributes to tear film instability and is variable with prolonged VDT exposure. Our study indicated that the tear film stability was determined by blinking quality, and the predominance of blinking type relates to tear film stability.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/OPX.0b013e31829962ec | DOI Listing |
Ophthalmol Ther
January 2025
Santa Barbara Eye Care, Santa Barbara, CA, USA.
Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.
View Article and Find Full Text PDFCornea
November 2024
Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY.
Purpose: To visualize the behavior of perfluorohexyloctane (PFHO), an eye drop to treat dry eye disease (DED), on the surface of saline in vitro and on the human ocular surface using infrared emissivity.
Methods: Emissivity videos were used to measure the spreading and disappearance rates of PFHO on saline (with and without mucin for spreading rate) and layered over a 125 nm film of meibum on the surface of saline using a TearView camera. Ocular surface emissivity was videoed in a volunteer without DED before and after instillation of 1 drop of PFHO.
Eye Contact Lens
November 2024
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, China.
Objectives: To evaluate the impact of scleral contact lens (SL) wear on the visual quality and the ocular surface wettability in myopic patients with regular corneas.
Methods: This prospective, randomized, controlled study enrolled a total of 80 myopes with regular corneas. Subjects were randomly allocated to wear SL or rigid corneal lens (RCL) for 3 months.
Background: Overexpression of tear matrix metalloproteinases-9 (MMP-9) on the ocular surface tissues has been reported to result in ocular surface damage. MMP-9 levels in tears have been listed as one of many tools for confirming dry eye disease (DED).
Objective: This investigation aimed to compare MMP-9 levels and ocular surface parameters in diabetic patients with and without DED.
Expert Opin Pharmacother
January 2025
Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Introduction: Meibomian Gland Dysfunction (MGD) represents the most common cause of dry eye disease (DED). Traditional treatments mainly rely on heating and liquifying the meibum to favor its expression. However, recent knowledge advances have led to the development of novel therapies specifically designed for patients with MGD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!